Predicted Trait | |
Reported Trait | Type 2 diabetes (based on SNPs involved in insulin resistance) |
Mapped Trait(s) | type 2 diabetes mellitus (MONDO_0005148) |
Score Construction | |
PGS Name | GRSIR |
Development Method | |
Name | Genome-wide significant variants |
Parameters | Index SNPs or their proxies (using T2D weights) |
Variants | |
Original Genome Build | NR |
Number of Variants | 10 |
Effect Weight Type | NR |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000020 |
Citation (link to publication) | Vassy JL et al. Diabetes (2014) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 100% 69,033 individuals (100%) |
PGS Evaluation | European: 66.7% African: 33.3% 3 Sample Sets |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST005047 Europe PMC: 22885922 |
69,033 individuals | European | NR |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM000068 | PSS000044| European Ancestry| 3,471 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 0.98 [0.93, 1.04] | — | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model" |
PPM000069 | PSS000043| European Ancestry| 1,650 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 1.01 [0.91, 1.12] | — | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model" |
PPM000070 | PSS000042| African Ancestry| 820 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 1.06 [0.99, 1.15] | — | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model", SNPs were not weighted by their effect size as the betas were measure in Europeans |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000044 | T2D was defined by a fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL) or report of taking diabetes medications | — | [ ,
46.6 % Male samples |
— | European | — | FOS | — |
PSS000042 | T2D was defined by a fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL) or report of taking diabetes medications | — | [ ,
38.8 % Male samples |
— | African American or Afro-Caribbean | — | CARDIA | — |
PSS000043 | T2D was defined by a fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL) or report of taking diabetes medications | — | [ ,
46.5 % Male samples |
— | European | — | CARDIA | — |